DRUG earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -31.34. Updated 2026-07-23.
Bright Minds Biosciences (DRUG) Research Hub
Bright Minds Biosciences (DRUG) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 63.18 USD (-2.89%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -31.34, market cap 0.59B. This hub links to the full technical, earnings and options research available for DRUG.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 63.18 USD (-2.89%) |
| 52-week range | 58.11 USD – 87 USD |
| Trend regime | Range |
| 14-day RSI | 29.4 (Oversold) |
| Trailing P/E | -31.34 |
| Market cap | 0.59B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for DRUG
Covered Call on DRUG: how it works, illustrative setup around the real 63.18 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DRUG: how it works, illustrative setup around the real 63.18 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DRUG: how it works, illustrative setup around the real 63.18 USD price, max profit/loss, breakeven and when to use it. Educational.
DRUG technical analysis: range, last 63.18 USD, RSI 29.4, 52w range 58.11 USD–87 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is DRUG in?
Bright Minds Biosciences (DRUG) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is DRUG in an uptrend or downtrend?
As of 2026-09-11, DRUG is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DRUG's trailing P/E ratio?
DRUG's trailing P/E is -31.34, with a market cap of 0.59B. See the earnings research page for full valuation detail.
When does DRUG next report earnings?
DRUG is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -1.28313 USD.